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http://dx.doi.org/10.1016/j.ccell.2015.09.006SUMMARYThe discovery of long non-coding RNA (lncRNA) has dramatically altered our understanding of cancer. Here,
we describe a comprehensive analysis of lncRNA alterations at transcriptional, genomic, and epigenetic
levels in 5,037 human tumor specimens across 13 cancer types from The Cancer Genome Atlas. Our results
suggest that the expression and dysregulation of lncRNAs are highly cancer type specific comparedwith pro-
tein-coding genes. Using the integrative data generated by this analysis, we present a clinically guided small
interfering RNA screening strategy and a co-expression analysis approach to identify cancer driver lncRNAs
and predict their functions. This provides a resource for investigating lncRNAs in cancer and lays the ground-
work for the development of new diagnostics and treatments.Significance
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INTRODUCTION
Cancer is a genetic disease involving multi-step changes in the
genome. The human genome contains 20,000 protein-coding
genes (PCGs), representing less than 2% of the total genome
(Ezkurdia et al., 2014), whereas up to 70% of the human genome
is transcribed into RNA, yielding many thousands of non-coding
RNAs (Derrien et al., 2012; Mattick and Rinn, 2015). Long non-
coding RNAs (lncRNAs) are operationally defined as transcripts
that are larger than 200 nt that do not appear to have protein-
coding potential (Kapranov et al., 2007; Mattick and Rinn,
2015). Similar to protein-coding transcripts, transcriptional
control of lncRNAs is subject to typical histone modification-
mediated regulation, and lncRNA transcripts are processed
by the canonical spliceosome machinery (Cabili et al., 2011;
Derrien et al., 2012; Guttman et al., 2009; Ravasi et al., 2006).
Compared with their protein-coding counterparts, lncRNA
genes are composed of fewer exons, are under weaker selective
constraints during evolution, and are present in relatively lower
abundance. Notably, the expression of lncRNAs is strikingly
cell type and tissue specific (Cabili et al., 2011; Mercer et al.,
2008; Ravasi et al., 2006) and, in many cases, even primate spe-
cific (Derrien et al., 2012). LncRNAs can serve as scaffolds or
guides to regulate protein-protein or protein-DNA interactions,
as decoys to bind proteins or microRNAs (miRNAs), and as en-
hancers to influence gene transcription, when transcribed from
enhancer regions or their neighboring loci (Batista and Chang,
2013; Guttman and Rinn, 2012; Karreth and Pandolfi, 2013;
Lee, 2012; Mattick and Rinn, 2015; Mercer et al., 2009; Morris
and Mattick, 2014; Ørom and Shiekhattar, 2013; Prensner and
Chinnaiyan, 2011; Ulitsky and Bartel, 2013). Importantly, rapidly
accumulating evidence indicates that lncRNAs are associated
with chromatin-modifying complexes and guide epigenetic
regulations in both physiological and pathological conditions
(Mercer and Mattick, 2013).
Recent studies suggested that lncRNA is involved in the initi-
ation and progression of cancer. In addition to the fact that
they are highly deregulated in tumors (Akrami et al., 2013; Calin
et al., 2007; Du et al., 2013; Iyer et al., 2015; Kim et al., 2014;
Li et al., 2015; Ling et al., 2013; Prensner et al., 2011; Trimarchi
et al., 2014; Xing et al., 2014), lncRNAs have been found to
act as tumor suppressors or oncogenes. Therefore, a compre-
hensive genomic characterization of lncRNA alterations across
major cancers not only is urgently needed but may lead to new
diagnostic and therapeutic strategies for cancer. The Cancer
Genome Atlas (TCGA) project is a coordinated effort to accel-
erate our understanding of themolecular basis of cancer through
the application of genomic analysis technologies. Here, we per-
formed a multiplatform integrative analysis of lncRNA alterations
in 5,037 of cancers from 13 tumor types in TCGA project.
RESULTS
The Expression of lncRNAs Is Dysregulated in Cancer
We analyzed RNA sequencing (RNA-seq) profiles from 5,037
tumors across 13 cancer types as well as 424 normal specimens
from nine matching tissue types in TCGA (Table S1). An
evidence-based lncRNA transcript annotation that contains
13,562 manually annotated lncRNA genes from the GENCODE530 Cancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc.consortium (V18) was used to define lncRNAs. To evaluate the
analysis reliability of the workflow for RNA-seq data in the pre-
sent study, we compared 520 breast specimens whose RNA
expression had been analyzed by both RNA-seq and microarray
in TCGA. The transcriptomic correlations of RNA expression
determined by RNA-seq (reads per kilobase per million mapped
reads [RPKM]) and by microarray were calculated in a total of
13,318 PCGs and lncRNAs. In more than 96.7% of genes
analyzed, significant and positive correlations were observed
between the RPKM- and microarray-derived RNA expression
levels (Figures S1A and S1B). To ensure detection reliability
and reduce background noise, we applied two filters in each
cancer type: the first eliminates any gene whose 50th-percentile
RPKM value is equal to 0, and the second selects only
genes whose 90th-percentile RPKM value is greater than 0.1.
On average, 4,409 lncRNAs (32.51% of those annotated by
GENCODE) were detected in each cancer type. Of these,
2,316 lncRNAs (17.08%) were commonly detected in all 13
cancer types, and 8,179 lncRNAs (60.31%) were detected in at
least one cancer type (Table S2 and Figure S1C). The lncRNAs
detected in each cancer type are listed in Table S2.
To characterize tumor-associated dysregulation of lncRNA
expression, we analyzed lncRNA expression in seven cancer
types for which the number of corresponding normal tissue
samples analyzed by RNA-seq was greater than 20 (Figure 1A).
Compared with their normal counterparts, the seven cancer
types had on average 15.00% and 11.18% of lncRNAs signifi-
cantly up- and downregulated, respectively (Figure 1B). The
lncRNAs whose RNA expression was significantly altered in
each cancer type are listed in Table S2. Using the same pipeline,
we also calculated the percentages of dysregulated PCGs and
found that lncRNAs and PCGs have similar percentages of
tumor-associated dysregulation of expression (Figure 1B). By
comparing the dysregulated lncRNAs in different cancer types,
we found that 60% of these altered lncRNAs were cancer-
type specific, and the rest were shared by at least two cancer
types (Figures 1C, 1D, and S1D). We identified only five lncRNAs
whose RNA expression was significantly altered in all seven
cancer types (Figure 1E). The expression of many previously
identified tumor-associated lncRNAs was found to be signifi-
cantly dysregulated in multiple cancer types. For example, the
oncogenic lncRNAs PCAT7, PVT1, and HOTAIR were signifi-
cantly upregulated in six, five, and four cancer types, respec-
tively. The lncRNAs whose dysregulated expression was shared
or unique among different cancer types are listed in Table S2.
Importantly, the percentage of cancer type-unique dysregulated
lncRNAs was remarkably higher than that of PCGs (Figures 1C–
1F), although lncRNAs and PCGs have similar percentages
of global dysregulation. Together, this demonstrates that the
dysregulation of expression of lncRNA is common in cancer.
Although most lncRNAs showing dysregulated expression are
cancer type unique, a small number of alterations are shared
among different cancer types.
Somatic Copy Numbers of lncRNA Genes Are Altered
in Cancer with Different Frequencies
We analyzed the somatic copy number alterations (SCNAs) of
lncRNAs in cancer via SNP microarray analysis of 5,860 tumors
in 13 cancer types from TCGA. For each cancer type, the SCNA
Figure 1. The Expression of lncRNAs Is Dysregulated in Cancer
(A) Heatmap of lncRNAs whose expression is significantly dysregulated. The top 100 most significantly dysregulated lncRNAs from each individual tumor type
are presented.
(B) The percentages of the dysregulated lncRNAs and PCGs.
(C and D) The percentages of the upregulated (C) and downregulated (D) lncRNAs (left) and PCGs (right) that were shared among the seven cancer types.
(E and F) Venn diagrams of the upregulated (left) and downregulated (right) lncRNAs (E) and PCGs (F) shared among the seven cancer types.
See also Figure S1 and Tables S1 and S2.frequencies of the lncRNA-containing loci were calculated (Fig-
ures 2A and 2B). When ‘‘high-frequency alteration’’ was defined
as an alteration that occurs inmore than 25%of the specimens in
a given cancer type, few lncRNA gene loci had concurrent high-
frequency gain and loss in the same type of cancer (Figure S2A).
Across all 13 cancer types, there were on average 13.16% and
13.53% of lncRNA genes with high-frequency gain and loss,
respectively (Figures 2A–2C; Table S3). Although ovarian serous
cystadenocarcinoma (OV) and lung squamous cell carcinoma
(LUSC) had the most lncRNAs with high-frequency SCNAs,
very few lncRNAs in prostate adenocarcinoma (PRAD) and acute
myeloid leukemia (LAML) had high-frequency alterations (Fig-
ures 2A and 2C).
To characterize the focal SCNAs that harbor lncRNA
genes, we retrieved the location information of focal genomicCalteration peaks from the Firehose project and mapped the
lncRNA-containing loci to these focal alteration regions in
each cancer type (Figure S2B and Table S3). In LUSC, for
example, totals of 435 and 1,811 lncRNA genes were mapped
to regions with focal gains and losses, respectively (Figure 2D).
The lncRNA genes located in the focal alteration regions
in other cancer types are shown in Figure S2B. Many previ-
ously identified tumor-associated lncRNAs were found to
be associated with focal SCNAs in multiple cancer types.
For example, the oncogenic lncRNAs FAL1(FALEC) and
PVT1 were focally amplified in seven and six cancer types,
respectively.
To estimate the contribution of SCNAs to lncRNA dysregula-
tion in cancer, we analyzed the correlation between lncRNA
copy number and RNA expression level for all detectableancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc. 531
Figure 2. Somatic Copy Numbers of lncRNA Genes Are Altered in Cancer with Different Frequencies
(A) A genome-wide view of SCNAs in cancers. The outer track shows the frequencies of SCNAs from the lncRNA-containing loci, and the inner track shows the
focal alteration regions.
(B) An enlarged view of SCNAs in LUSC.
(C) Heatmap of somatic copy number gain and loss for lncRNA genes. The rows, each of which represents an lncRNA gene locus, are arranged according to the
genomic locations of the lncRNA genes. Left: frequency of gain (red); right: frequency of loss (blue).
(D) The lncRNA and PCGs in the top 20 focal gain (left) or loss (right) peaks in LUSC. The numbers of PCGs (left), annotated lncRNAs (middle), and detectable
lncRNAs (right) in each peak are indicated in parentheses.
(E and F) Histogram of percentage of lncRNAs whose RNA-SCNA correlation coefficients are in specific ranges across 13 cancer types (E) and in each cancer
type (F). The number and red color intensity in the insets indicate the percentage of the detectable lncRNAs whose Pearson’s R values were R0.2 in a given
cancer type.
See also Figure S2 and Tables S3.lncRNAs in each cancer type. In summary, for 36.27% of the
lncRNAs, there were positive correlations (R R 0.2) between
their RNA expression levels and their gene copy numbers
(Figure 2E). Importantly, cancer types that had higher levels
of SCNAs (such as OV and LUSC) demonstrated stronger532 Cancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc.RNA-SCNA correlations than the cancer types with fewer
SCNAs (such as LAML and PRAD) (Figure 2F). This suggests
that SCNAs are an important mechanism that leads to the
dysregulation of lncRNAs in cancer, especially for those cancer
types whose genomes contain abundant SCNAs.
Figure 3. DNA Methylation Patterns in the Promoter Regions of lncRNA Genes Are Altered in Cancer
(A) NMF clustering of DNA methylation probes that are located in lncRNA promoters and whose methylation b values had the largest variations across all breast
specimens.
(B) Heatmaps of the methylation status (b value, top) in the promoter regions and the RNA expression level (bottom) of the corresponding lncRNAs in breast
specimens.
(C) Heatmaps of the methylation status of the lncRNA promoter regions and the RNA expression levels.
(D) A summary of the percentage of the CAESLG.
See also Figure S3 and Tables S4 and S5.DNA Methylation Patterns in the Promoter Regions of
lncRNA Genes Are Altered in Cancer
We analyzed DNA methylation alterations in the promoter re-
gions of lncRNAs in cancers. DNA methylation microarray pro-
files on 2,791 tumor and 467 normal specimens across seven
cancer types were obtained from TCGA. A total of 35,696 probes
corresponding to the promoter regions of the 2,435 lncRNA
genes whose expression was analyzed by RNA-seq were identi-
fied (Table S4). On average, the promoter region of each lncRNA
gene was covered by 15 probes. We first used consensus non-
negative matrix factorization (NMF) clustering analysis to cluster
samples according to their methylation profiles in each cancer
type. This revealed that for all seven cancer types studied, the
DNA methylation profiles of lncRNA genes from normal samples
were very similar within the cancer type, while the DNA methyl-
ation patterns of lncRNA genes from tumor samples were quite
diverse (Figures 3A and S3). It suggests that the promoter re-
gions of lncRNAs are subjected to DNA methylation-mediated
epigenetic alterations during tumorigenesis. Next, we applied
four separate filtering criteria to screen for cancer-associated
epigenetically silenced lncRNA genes (CAESLG) (Figures 3B
and 3C). On average, 3.92% of lncRNA genes had both hyper-
methylated promoters and reduced RNA expression in tumors
compared with their normal counterparts (Figure 3D). The
CAESLG candidates of each cancer type are listed in Table
S4. These findings suggest that epigenetic silencing of lncRNA
genesmay be amechanism that contributes to the dysregulationCof expression of lncRNAs in cancer. Because the probes for
many lncRNA genes were not available in the DNA methylation
microarray platform, some lncRNAs that are epigenetically regu-
lated may not be identified in our analysis.
Many Cancer-Associated SNPs Are Located in lncRNA
Loci
Using 5 kb as the cutoff distance between an annotated tran-
script and a cancer-associated SNP, we re-mapped all can-
cer-associated SNPs reported by the National Human Genome
Research Institute Catalog of Published Genome-Wide Associa-
tion Studies (GWAS) (Table S5) to genes annotated by the
Encyclopedia of DNA Elements. We found that 11.75% of the
index SNPs were near loci harboring lncRNA genes (Table S5).
The percentages of index SNPs close to PCGs, pseudogenes,
and other genes were 54.75%, 3.75%, and 3.38%, respectively
(Figure 4A). We further reasoned that only genes expressed in
tumor tissues have the potential to be functionally involved in
cancer development. By analyzing RNA-seq profiles from
TCGA in the nine cancer types for which both GWAS SNP and
TCGA RNA-seq information were available and combining the
expression analysis with the above findings regarding SNP-
associated lncRNA, we identified lncRNAs that are both close
to index SNPs and that express detectable transcripts in tumors
(Table S5). In PRAD, for example, 24 lncRNAs were found to
reside near 28 index SNPs. Among these 24 lncRNAs, 6 were
detected in prostate tumors (Figure 4B).ancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc. 533
Figure 4. Many Cancer-Associated SNPs Are Located in lncRNA Loci
(A) A genome-wide view of the most significant cancer-associated index SNPs. The peaks in each track are proportional to the p values between the chro-
mosomal locations of the index-SNPs.
(B) Genome-wide view of the breast (top) and prostate (bottom) index SNPs in lncRNA (red) and PCG loci (green).The Expression of lncRNAs Is a Specific Biomarker in
Cancer
To evaluate the potential value of lncRNAs as biomarkers in can-
cer, we first asked whether the expression signature of lncRNAs
can differentiate between tumors and their corresponding
normal tissues. In all nine tumor types in which both tumor and
normal tissues were available, we were able to use unsupervised
cluster analysis to differentiate normal tissues from tumors.
Although the expression of lncRNAs in tumor demonstrated
diverse patterns, the expression in normal tissue was relatively
homogeneous and could be clearly separated from the expres-
sion patterns in tumor tissues (Figures 5A, 5B, and S4A). To
further examine the value of lncRNAs as biomarkers, we chose
to study breast cancer, because it is a heterogeneous cancer
type with well-characterized pathological and molecular sub-
types. We selected 817 breast tumors for which the molecular
subtype had been defined by the University of California, Santa
Cruz, Cancer Genome Browser. A cluster analysis showed that
the unsupervised lncRNA expression subtypes demonstrated a
high correlation with the defined PAM50 subtypes and also
had a high correlation with clinical subtypes (Figure 5C). In
particular, almost all of the basal-like/triple-negative breast
tumors were clustered together and clearly separated from other
tumor and normal tissue samples. Importantly, it has been re-
ported that lncRNA expression is strikingly tissue and cell type
specific compared with PCGs in normal tissues (Cabili et al.,
2011; Mercer et al., 2008; Ravasi et al., 2006). We decided to
compare the tissue specificity among lncRNAs, PCGs, and
pseudogenes in cancer. We used an entropy-based metric534 Cancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc.that relies on Jensen-Shannon (JS) divergence to calculate
specificity scores (Cabili et al., 2011) for each gene in breast
specimens and found that the expression of lncRNA demon-
strated the highest subtype specificity, followed by pseudo-
genes, while PCGs demonstrated the least subtype specificity
(Figure 5D). About 18.27% of lncRNAs showed subtype speci-
ficity, whereas only 10.55% of PCGs were subtype specific (Fig-
ure 5E). To rule out the possibility that the higher specificity of
lncRNAs is a result of their lower abundance, we calculated
the specificity scores of highly expressed transcripts from these
three different types of genes. Again, lncRNA showed a higher
tissue specificity than PCG and pseudogenes (Figure 5D).
We also sought to determine if the expression signatures of
lncRNAs are also cancer type specific using RNA-seq profiles
from the Cancer Cell Line Encyclopedia (CCLE) in 935 human
tumor cell lines (Table S6). As shown in Figure 5F, tumors of
epithelia, melanoma, hematological, and neurological origins
formed distinctive clusters on the basis of lncRNA expression.
Sarcoma tumors displayed a diffuse lncRNA expression pattern,
which may be explained by the fact that this type of tumor arises
from various tissues. Using the JS divergence calculation, we
compared the tissue specificity of lncRNAs, PCGs, and pseudo-
genes. Similar to our findings regarding subtype specificity in
TCGA, the JS divergence measurements across cell lines of
different origins revealed that lncRNA are more tissue specific
than PCGs and pseudogenes (Figure 5G). Finally, we compared
cancer type specificity across cell lines from 22 cancer types,
and consistent results were observed (Figure S4B). These
studies suggest that lncRNAs have the potential to serve as
Figure 5. The Expression of lncRNAs Is a Specific Biomarker in Cancer
(A) Unsupervised hierarchical cluster analyses on the expression of the top 10% lncRNAs whose expression levels varied themost across all samples within each
cancer type.
(B) Heatmap generated by unsupervised cluster analysis of lncRNAs with the largest expression variation in kidney cancer.
(C) Heatmap of unsupervised hierarchical cluster analysis using lncRNA signatures from breast cancer.
(D) Distribution of maximal subtype specificity scores calculated for each gene across the breast cancer specimens for all expressing transcripts (top) or high
expressers (bottom) for lncRNA (blue), pseudogenes (red), and PCGs (black).
(E) Heatmap of lncRNA (left) and PCG (right) expression (JC scores) sorted on the basis of tissue-specific expression. Top: tissue specific; bottom: ubiquitously
expressed.
(F) Heatmap of unsupervised hierarchical cluster analysis using lncRNA signatures from the CCLE RNA-seq dataset.
(G) Distributions of maximal cancer type specificity scores calculated for each gene across the CCLEmajor cancer types and across all expressing genes (top) or
high expressers (bottom) for lncRNAs (blue), pseudogenes (red), and PCGs (black).
See also Figure S4 and Tables S6.
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specific biomarkers with potential applications in cancer predic-
tion, early detection, and diagnosis. Notable, unknown primary
origin tumors account for 3%–5% of all new cancer cases and
are aggressive diseases with poor prognosis. Our data indicate
that lncRNAs may serve as informative biomarkers to determine
the origin of these tumors.
lncRNome Profiles Provide a Resource to Functionally
Identify Cancer Driver lncRNAs
We hypothesized that, using the TCGA lncRNome information as
a clinical filter, we would be able to generate a concentrated
and clinically relevant lncRNA list that could be used for a
candidate-oriented functional screening. To test the concept,
we chose breast cancer as an example and evaluated a four-
step procedure to identify for potential driver lncRNAs (Fig-
ure 6A). In summary, we identified 19 lncRNAs that have
cancer-associated genomic alterations and are also correlated
with patient survival (Table S7). In a proof-of-concept screen-
ing, we found that all four small interfering RNAs (siRNAs) specif-
ically targeted ENSG00000253738 (breast cancer associated
lncRNA8 [BCAL8]) significantly reduced the proliferation of
MDA-MB-231 cells (Figure 6B). BCAL8 is the neighbor transcript
of OTUD6B (Xu et al., 2011), and they share overlapping pro-
moter regions. Further analysis of SNP arrays revealed that the
BCAL8 gene was gained in 49.7% of breast cancer (Figure 6C).
Importantly, both higher expression ofBCAL8RNA and genomic
gain of the BCAL8 gene were significantly associated with
decreased survival in breast cancer (Figure 6D). There was
also a strong positive correlation between BCAL8 RNA ex-
pression and its genomic copy number in the breast tumors
(Figure 6E). With the vast amount of data available in TCGA
lncRNome, we had the resources to expand our characterization
of BCAL8 from breast cancer to other cancer types. Interest-
ingly, we found that higher expression of BCAL8 RNA was also
significantly correlated with poor clinical outcome in OV, uterine
corpus endometrial carcinoma (UCEC), and LAML (Figure S5A).
Although BCAL8 was significantly gained in OV and UCEC,
this was not the case for LAML (Figure S5B). To further validate
the function of BCAL8, we suppressed BCAL8 expression by
small hairpin RNA (shRNA) in breast and ovarian cancer cell
lines. We consistently found that the expression of BCAL8-
shRNAs significantly reduced growth rates in all cell lines tested
(Figure 6F). Moreover, downregulating BCAL8 expression also
significantly reduced anchorage-independent growth in cells
(Figures 6G and 6H). Finally, we injected cells expressing control
and BCAL8-specific hairpins into nude mice and found that the
expression of the BCAL8-shRNAs significantly suppressed
tumor growth in vivo (Figure 6I). Together, this describes a strat-
egy to integrate multidimensional molecular profiles with clinical
annotations to generate clinical parameter-specific candidates
for genetic screening.
lncRNome Profiles Provide a Resource to Infer lncRNA
Functions
Predicting the biological functions of lncRNAs is challenging.
Guilt-by-association (GBA) analysis has been proposed that the
function of a poorly characterized lncRNA gene can be inferred
on the basis of known functions of PCGs with which it is co-
expressed (Huarte et al., 2010). Because TCGA provides multi-536 Cancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc.omic profiles in large scale, it may serve as an excellent resource
for GBA-based lncRNA function prediction. To test this concept,
we conducted GBA analysis for BCAL8. The RNA-seq profiles
were analyzed to identify PCGs whose expression was signifi-
cantly correlated with BCAL8 expression in three cancer types
(Figure 7A). We found that 38.2% (958 of 2,500) of BCAL8-asso-
ciated PCGs were shared by all three cancer types (Figure 7B).
Next, we performed gene ontology analysis on the BCAL8-
associated PCGs that were common across the three cancer
types and found that the most over-represented pathway in
BCAL8-associated genes was the cell cycle pathway (Figures
7C and 7D). We also performed a GBA analysis for BCAL8 using
a protein expression profile (reverse phase protein array [RPPA])
of breast cancer from TCGA and identified 37 proteins (anti-
bodies) whose expression levels were significantly and positively
correlated with BCAL8 expression (Figure 7E and Table S8).
Consistent with the above RNA-based GBA analyses, many
BCAL8-associated proteins were key regulators in cell-cycle
pathways. For example, we found that BCAL8 expression was
significantly and positively correlated with cyclin E2 at both the
mRNA and protein levels. We knocked down BCAL8 expression
in cancer cell lines and analyzed cell-cycle profiles. Consistent
with our GBA prediction, knocking down BCAL8 dramatically
inhibited the G1-S transition of the cell cycle (Figure 7F). Finally,
supporting our GBA analysis, suppressing BCAL8 expression
significantly reduced both CCNE2 mRNA and cyclin E2 protein
levels (Figures 7G and 7H). In summary, using BCAL8 as an
example, we described an integrated bioinformatic approach
to elucidate the function of given lncRNAs using information
from the lncRNome dataset of TCGA (Figure S6).
DISCUSSION
Before the discovery of non-coding RNAs, the search for cancer
drivers was focused on PCGs that resided in recurrent alter-
ations in cancer genomes. However, many of these recurrent
alterations were found to either be located in ‘‘gene desert’’
regions, or they contained no cancer-linked PCGs. The lack of
PCGs in cancer-associated genetic alterations is further sup-
ported by the fact that only 2% of the human genome encodes
proteins. These findings, in combination with the recent revela-
tion that about 70% of the human genome is transcribed into
RNA, strongly suggest that non-coding RNAs play significant
roles in tumor development. Our study represents the one of
largest analyses so far of lncRNA dysregulation at transcrip-
tional, genomic, and epigenetic levels across cancers, sub-
stantially expanding our knowledge of non-coding RNAs in the
cancer genome (the data generated from this study are available
at http://tcla.fcgportal.org). Given that the majority of the human
genome is transcribed to RNA, while only a small portion of these
transcripts encode proteins, the number of lncRNA genes may
be very large. An important challenge is that the genome-wide
annotation and functional characterization of lncRNAs is still in
its infancy. Further efforts will be needed to de novo annotate
and characterize cancer unique lncRNA transcripts (Iyer et al.,
2015; Trimarchi et al., 2014).
The expression of lncRNAs is strikingly cell type specific in
normal tissues (Cabili et al., 2011; Mercer et al., 2008; Ravasi
et al., 2006). Our results indicate that the expression of lncRNA
Figure 6. An Effective Strategy to Integrate Multidisciplinary Information from TCGA to Identify Cancer Driver lncRNAs
(A) Flowchart describing the process of candidate gene selection in breast cancer.
(B) The summary of the proof-of-concept siRNA screening in MDA-MB-231 cells.
(C) Copy number profiles of BCAL8 locus from breast tumor specimens.
(D) Survival curves of breast cancer patients with high and low BCAL8 RNA expression (left) and differing genomic SCNA status (right). The numbers of patients
who were alive (at risk), deceased (event), and censored during the course of surveillance are indicated in the table under the corresponding time points.
(E) The correlation between BCAL8 gene copy number and RNA expression in breast cancer.
(F) The growth curves of cells expressing control or BCAL8 shRNAs.
(G) Soft-agar assays (in six-well plates) on cells expressing control or BCAL8 shRNAs.
(H) Quantification of the number of colonies from the softer agar assays.
(I) Xenograft tumor growth of cells expressing control or BCAL8 shRNAs. The error bars indicate SD. *p < 0.05.
See also Figure S5 and Table S7.
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Figure 7. Inferring the Functions of BCAL8 by Integrative Bioinformatics Analyses
(A) Heatmap of PCGs that were significantly and positively co-expressed with BCAL8. The genes were arranged from top to bottom in ascending order of their
correlation with BCAL8.
(B) Venn diagrams of BCAL8-associated genes among breast, ovarian, and endometrial cancers.
(C) Pathways over-represented by BCAL8-associated PCGs in all three cancer types according to DAVID analysis on the basis of gene ontology term.
(D) Enrichment of cell-cycle pathway genes in cancer specimens with high levels of BCAL8.
(E) Heatmap of PCGs whose protein expression (RPPA) is significantly correlated with BCAL8 expression in breast cancer. The proteins are arranged from top to
bottom in ascending order of their correlation with BCAL8 expression.
(F) Cell-cycle profiles of cells expressing control and BCAL8 shRNAs.
(G) Quantitative RT-PCR (qRT-PCR) of CCNE2 mRNA expression in cells expressing control or BCAL8 shRNAs.
(H) Western blot of cylin E2 in cells expressing control or BCAL8 shRNAs. The error bars indicate SD. *p < 0.05.
See also Figure S6 and Table S8.has the highest cancer type specificity, followed by pseudo-
genes, and then PCGs, which were the least subtype specific.
The expression of lncRNAs is frequently dysregulated in cancer.
There are sensitive, rapid, low-cost methods readily available for
lncRNA quantification. Additionally, lncRNAs often form second-538 Cancer Cell 28, 529–540, October 12, 2015 ª2015 Elsevier Inc.ary structures that are relatively stable, thereby facilitating their
detection as free RNAs in body fluids such as urine and blood.
Therefore, lncRNAs may be an ideal class of biomarkers with
potential applications in cancer prediction, early detection, diag-
nosis and classification.
The TCGA project has profiled large numbers of tumors to
identify molecular aberrations at multi-omic levels. Extracting
valid information from TCGA can deepen our understanding of
tumorigenesis and lead to the development of therapeutics.
However, because cancer genomes are highly unstable, many
cancer-associated alterations are not the causes but instead
the consequence of tumorigenesis. The main challenge in
developing effective therapies is to identify cancer driver genes,
which once targeted by therapeutic agents can suppress or
eliminate tumor growth. Analyses of genome-wide molecular
profiles using various bioinformatics approaches can reveal
genomic alterations during cancer initiation and progression
but cannot distinguish ‘‘causal’’ from ‘‘bystander’’ genetic
alterations. Genome-wide functional screening approaches
have been used with some success in identifying cancer driver
genes; however, this approach can be time and labor intensive
and, more important, susceptible to finding false positives and
fraught with large numbers of false negatives. Here, we have
developed a clinically guided genetic screening approach to
identify functional lncRNAs in cancer. Using the cancer
lncRNome resource generated in our study as biological and
clinical filters, we were able to generate a relatively short list of
lncRNA candidates for more extensive testing using candidate-
oriented genetic screening. Predicting the biological functions
of a given lncRNA is challenging. A ‘‘co-expression’’ approach
has been used as one approach to begin to achieve an under-
standing of lncRNA function (Huarte et al., 2010). Because the
level of lncRNA expression may directly represent its biological
function in cancer, we proposed predicting lncRNA functions
by co-expression analysis, that is, by identifying the PCGs
whose expression are significantly correlated with the expres-
sion of a given lncRNA. TCGA contains multi-omic profiles of
large-scale samples, serving as an excellent resource for co-
expression analysis. Taken together, the lncRNome database
generated in the present study provides a resource to effectively
identify cancer driver lncRNAs and predict their functions in
cancer, which will lead to a greater understanding of molecular
mechanisms of cancer, and should lead to clinical applications
in oncology.EXPERIMENTAL PROCEDURES
Annotation of lncRNAs, PCGs, and Pseudogenes
The GENCODE lncRNA annotation (V18), a manually curated and evidence-
based lncRNA annotation containing 13,562 genes and 23,105 transcripts,
was used to define lncRNA genes. The GENCODE whole annotation (V18)
was used to define PCGs and pseudogenes, resulting in a PCG set containing
20,318 genes and 81,673 transcripts, a pseudogene set containing 14,181
genes and 17,517 transcripts, and an ‘‘other genes’’ set containing 9,384
genes and 73,289 transcripts.
RNA-seq Data Processing
RNA-seq files were downloaded from the Cancer Genomics Hub (http://
cghub.ucsc.edu). We imported the aligned reads of each BAM file to the
Partek Genomic Suite (http://www.partek.com) to obtain the expression levels
for genes by summarizing the RPKM values. For each cancer type, we applied
two filters to eliminate unreliability in the measurements of genes: (1) the 50th
percentile of the RPKM values is larger than 0, and (2) the 90th percentile of
the RPKM values is larger than 0.1. The genes that passed these two filters
were defined as detectable in a given cancer type. Please see Supplemental
Experimental Procedures for a detailed discussion of procedures.CXenograft Model In Vivo
6- to 8-week-old female nudemice were used for the xenograft assays. A2780
cells and MDA-MB-231 cells were trypsinized and harvested in PBS, then a
total volume of 0.1 ml PBS containing A2780 cells (1 3 106) or MDA-MB-231
cells (1.5 3 106) were injected subcutaneously into the flanks of the animals.
The animal study protocol was reviewed and approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania. Please
see Supplemental Experimental Procedures for a detailed discussion of
procedures.
Statistical Analysis
Statistical analysis was performed using SPSS and SAS software. All results
were expressed as mean ± SD, and p < 0.05 indicated significance. The
survival curves were constructed according to the Kaplan-Meier method
and compared with the log rank test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.09.006.
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